BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 9190308)

  • 1. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
    Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience.
    Perrella A; Esposito C; Ioia G; Campanella L; Taglialatela D; Cuomo O
    Transplant Proc; 2010 May; 42(4):1226-8. PubMed ID: 20534267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N; Holman MJ; Yang HC
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytomegalovirus infection after heart transplantation. Retrospective analysis of an antiviral CMV prevention].
    Antretter H; Höfer D; Klaus A; Larcher C; Margreiter J; Margreiter R
    Dtsch Med Wochenschr; 2000 Apr; 125(15):445-51. PubMed ID: 10800441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
    Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
    J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
    Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
    Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
    Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
    Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
    Tryphonopoulos P; Weppler D; Morris MI; Russo C; Nishida S; Levi DM; Moon J; Tekin A; Selvaggi G; Island E; Arosemena L; Ruiz P; Tzakis AG
    Transplantation; 2011 Nov; 92(9):1051-7. PubMed ID: 21876474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.